Sorrento Initiates Enrollment in P-II MSC-COV-202BR Study for the Treatment of Acute Respiratory Distress due to COVID-19 in Brazil
Shots:
- The first patient has been enrolled at the first site in P-II MSC-COV-202BR efficacy study evaluates COVI-MSC vs PBO in 100 patients with COVID-19-induced ARD or ARDS in Brazil
- The primary objective of the study is to evaluate the efficacy of COVI-MSCs in patients with COVID-19-induced ARD or ARDS
- Additionally- the company plans to start the enrollment for two additional P-III studies with COVI-MSC across multiple sites in the US & Brazil
| Ref: Sorrento | Image: City Biz
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com